Skip to main content

2 Result(s)

within Yarong Li Remove this filter Biomedicine Remove this filter

and

  1. Article

    Open Access

    Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study

    HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report th...

    Yan Qin, Yong** Song, Dong Wang, Ou Bai, Jifeng Feng, **uhua Sun, Lihua Qiu… in BMC Cancer (2024)

    Download PDF (3171 KB) View Article

  2. Article

    Open Access

    Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease

    Common neurodegenerative proteinopathies, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are characterized by the misfolding and aggregation of toxic protein species, including the amyloid beta...

    Amit K. Chouhan, Caiwei Guo, Yi-Chen Hsieh, Hui Ye… in Acta Neuropathologica Communications (2016)

    Download PDF (4567 KB) View Article